One-Year Clinical Remission with Tezepelumab in Severe Asthma: TERESA Single-Arm Prospective Study - PubMed
4 hours ago
- #tezepelumab
- #severe asthma
- #clinical remission
- Tezepelumab achieved clinical remission in 34.6% of severe asthma patients after 52 weeks in the TERESA study, a single-arm prospective Phase 4 trial.
- Higher remission rates were observed in biologic-naïve patients (47.4%) compared to biologic-experienced patients (20.0%), with baseline blood eosinophils ≥300 cells/μL also predicting better outcomes.
- The study defined clinical remission by absence of exacerbations, no maintenance oral corticosteroids, ACQ-6 ≤1.5, and stable lung function, with a favorable safety profile noted for tezepelumab.